Related Experiment Video
Updated: May 10, 2026
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Updates in growth hormone treatment and mortality
Mark Sherlock1, Paul M Stewart
1Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK.mark.sherlock@amnch.ie
Current Opinion in Endocrinology, Diabetes, and Obesity
|June 29, 2013
Summary
Mortality is higher in hypopituitarism, especially for women, but is decreasing. Growth hormone (GH) therapy
Area of Science:
- Endocrinology
- Clinical Medicine
- Public Health
Background:
- Hypopituitarism is associated with increased mortality rates.
- This risk is particularly elevated in female patients.
- Recent trends suggest a decline in mortality towards general population levels.
Purpose of the Study:
- To review existing literature on mortality in hypopituitarism.
- To specifically examine the influence of growth hormone (GH) deficiency and GH therapy on mortality.
- To identify gaps and limitations in current research.
Main Methods:
- Literature review of studies on hypopituitarism and mortality.
- Analysis of data focusing on the impact of growth hormone (GH) therapy.
- Examination of retrospective and postmarketing surveillance data.
Main Results:
- Overall mortality in hypopituitarism is elevated, particularly in females, but shows a downward trend.
- Recent studies suggest GH therapy may not be associated with increased mortality.
- Conflicting findings exist regarding mortality in pediatric patients treated with GH, necessitating further investigation.
Conclusions:
- Available data on hypopituitarism mortality and GH therapy impact have significant limitations.
- Interpretation of current data requires careful consideration of these limitations.
- Further research is crucial to clarify the debated topic of GH therapy's effect on mortality in children treated with GH.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:27Major Hormones and Their Functions
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
01:10Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...